CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date Journal Article


Authors: Park, J. H.; Geyer, M. B.; Brentjens, R. J.
Article Title: CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date
Abstract: Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies. Although these CAR-modified T cells target the same antigen, the designs of CARs vary as well as several key aspects of the clinical trials in which these CARs have been studied. It is unclear whether these differences have any impact on clinical outcome and treatment-related toxicities. Herein, we review clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR design and production, and outline the limitations inherent in comparing outcomes between studies. © 2016 by The American Society of Hematology.
Journal Title: Blood
Volume: 127
Issue: 26
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2016-06-30
Start Page: 3312
End Page: 3320
Language: English
DOI: 10.1182/blood-2016-02-629063
PROVIDER: scopus
PMCID: PMC4929923
PUBMED: 27207800
DOI/URL:
Notes: Review -- Export Date: 2 August 2016 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Renier J Brentjens
    275 Brentjens
  2. Jae Hong Park
    246 Park
  3. Mark Blaine Geyer
    57 Geyer